Lucid Genomics
Lucid Genomics is a Berlin-based AI-powered platform for secondary and tertiary analysis of long-read sequencing data, serving clinical laboratories, research institutions, and pharmaceutical companies with variant detection, prioritization, and interpretation across the entire genome including the non-coding 'dark genome'.
- Company typePrivate
- Founded2024
- HeadquartersBerlin, Germany
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Lucid Genomics does
Lucid Genomics GmbH is a Berlin-based AI-powered bioinformatics company that operates a cloud-native secondary and tertiary analysis platform for long-read genomic sequencing data. Founded in 2024 as a spin-off from the Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin, the company targets clinical laboratories, healthcare providers, research institutions, and pharmaceutical/biotech organizations working on rare genetic disease diagnostics, cancer diagnostics, and drug discovery. The platform's core proposition is the analysis of 100% of the genome — including the non-coding 'dark genome' that comprises 98% of genetic material — through integration of 3D genome architecture (TAD regions), multi-omics data (RNA-seq, methylation, Hi-C, tissue-specific epigenetics), and proprietary AI algorithms for variant detection and prioritization.
The product suite is anchored by the Lucid Genome Suite and the Lucid Platform, supported by sub-products TADA (a disease-agnostic AI tool for prioritizing pathogenic copy number variants) and DICAST (a machine learning model for structural variant detection from short-read data, published as a bioRxiv whitepaper in May 2025). The platform is validated as a tertiary analysis compatibility partner for both PacBio HiFi long-read sequencing and Oxford Nanopore Technologies, with additional support for Illumina short-read, TELL-Seq linked-reads, and Bionano optical mapping inputs. Quantified performance claims include an 81% reduction in false-positive structural variants compared to other tools and a disease-specific scoring system exceeding 90% accuracy.
The company operates a B2B SaaS subscription model with quote-based enterprise pricing and a demo-driven sales motion. Distribution combines direct enterprise sales with ecosystem channel partnerships — notably PacBio and Oxford Nanopore for instrument-side distribution, and a QIAGEN co-marketing partnership for genomics workflow reach. The company is co-founded and led by Dr. Uirá Souto Melo (CEO) and Dr. M-Hossein Moeinzadeh (CTO), with Achim Geppert joining as CCO in February 2025 to lead commercial strategy. Scientific advisors include Prof. Dr. Stefan Mundlos and Prof. Dr. Martin Vingron from the founding institutions. As of the available data, Lucid Genomics has raised €1.3 million in pre-seed funding (led by Caesar Ventures, September 2024) plus €270K non-dilutive investment from MAX!mize and an EFRE grant through Investitionsbank Berlin.
Lucid Genomics firmographics
Firmographics- Name
- Lucid Genomics
- Legal name
- Lucid Genomics GmbH
- Website
- https://lucid-genomics.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lucid Genomics is a Berlin-based AI-powered platform for secondary and tertiary analysis of long-read sequencing data, serving clinical laboratories, research institutions, and pharmaceutical companies with variant detection, prioritization, and interpretation across the entire genome including the non-coding 'dark genome'.
- Ownership category
- akta.pro rank
Lucid Genomics industry classification
Industry- Product category
- Genomic Data Analysis Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
Keywords
Where Lucid Genomics is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Lucid Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- B2B SaaS Platform Subscription: Software-as-a-Service platform offering comprehensive DNA analysis solutions to healthcare and pharmaceutical industries. Platform is cloud-native and accessed via subscription model with demo and quote-based sales process.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Quote-based enterprise pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Lucid Genomics product offering
Product offeringCore offering
Lucid Genomics provides a cloud-native AI-powered SaaS platform for secondary and tertiary analysis of long-read genomic sequencing data. The platform analyzes 100% of the genome including coding and non-coding (dark genome) regions, performing variant detection, prioritization, interpretation, reporting, and clinical trial matching. It integrates multi-omics data (RNA-seq, methylation, Hi-C, epigenetics) and 3D genome architecture to support individual, family, and cohort-level analysis for clinical diagnostics, research, and drug discovery.
Product overview
Lucid Genomics offers a unified platform architecture centered on the Lucid Genome Suite and Lucid Platform for AI-powered genomic data analysis. The platform provides end-to-end capabilities from raw sequencing data to clinical interpretation, covering variant detection, prioritization, interpretation, reporting and trial matching. Key sub-products include TADA (disease-agnostic AI for CNV prioritization) and DICAST (ML model for SV detection from short-read data). The platform analyzes 100% of the genome including the non-coding 'dark genome', with multi-omics integration (RNA-seq, methylation, Hi-C, epigenetics) and supports both Individual, Family, and Cohort level analysis. Initial focus is on rare genetic diseases with expansion into cancer diagnostics and drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- Lucid Genome Suite: The company's flagship AI-powered genomic analysis platform for long-read sequencing data analysis, covering variant detection, prioritization, interpretation, reporting and trial matching.
Products and services
- Lucid Genome Suite AI-powered end-to-end bioinformatics platform for secondary and tertiary analysis of long-read genomic data, covering variant detection, prioritization, interpretation, reporting, and clinical trial matching. Includes cohort analysis tools, automated visualizations (IGV-like, Circos plots, TAD visualizations), HPO variant matching, multi-omics integration (RNA-seq, methylation, Hi-C), and 3D genome architecture analysis for clinical labs, research institutions, pharma and biotech customers.
Quantifiable outcome
- 81% reduction in false-positive structural variants (DEL, DUP, INS, INV) compared to other tools
- +3 more outcomes
Companies that use Lucid Genomics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Lucid Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability9 records
Feature9 records
Lucid Genomics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Oxford Nanopore TechnologiescoreCompatibility Partnership validating Lucid's tertiary analysis pipeline for interpretation of data generated using Oxford Nanopore sequencing. Pipeline processes basecalled, aligned, and variant-called nanopore sequencing data through annotation, variant classification, phenotype-driven case ranking, and methylation analysis.
- QIAGENcoreCo-Marketing Partnership. QIAGEN customers gain direct path to long-read native interpretation through Lucid Platform. Lucid customers benefit from access to QIAGEN's industry-leading genomics portfolio. Natural fit across genomics workflow.
- PacBiocoreCompatibility Partnership for tertiary analysis. Lucid's bioinformatics platform integrated into PacBio's Compatible partner program to strengthen tertiary analysis capabilities for long-read HiFi sequencing. Enables streamlined workflows from variant detection to clinical interpretation.
Scale indicators3 records
Recent moves7 records
Expansion highlights7 records
Lucid Genomics competitors and assessment
Company assessmentBroad incumbents
- Illumina DRAGEN: Illumina's DRAGEN platform is the dominant secondary/tertiary analysis suite for sequencing data. While primarily built for short-read Illumina data, it competes directly with Lucid for clinical genomic analysis budgets and customer mindshare across the same clinical lab and research institution buyer base.
- PacBio SMRT Link / HiFi Analysis Tools: PacBio's native analysis suite for HiFi long-read sequencing data. Lucid is a PacBio Compatible partner, so they are allies rather than head-to-head competitors, but PacBio's in-house analysis offering defines the baseline against which Lucid's tertiary layer is evaluated by HiFi customers.
- Oxford Nanopore EPI2ME: Oxford Nanopore's EPI2ME workflows provide native tertiary analysis for nanopore long-read data. Lucid is an ONT Compatibility partner, positioning as a complementary interpretation layer; EPI2ME is the incumbent Oxford Nanopore customers default to.
- QIAGEN Clinical Insight (QCI): QIAGEN's QCI Interpret is a leading clinical variant interpretation platform. QIAGEN is also a Lucid co-marketing partner, so the relationship is partially cooperative, but QCI competes for the same clinical interpretation budgets and pharma biomarker interpretation use cases Lucid targets.
Direct peers
- Congenica: Congenica provides clinical genomic interpretation software for rare disease diagnostics, competing directly with Lucid in the medical genetics and clinical laboratory segment served by hospitals like Charité and UCL.
- Fabric Genomics (formerly Omicia): Fabric Genomics offers AI-driven clinical genomic interpretation for rare disease and oncology. It directly overlaps with Lucid's clinical variant interpretation, prioritization, and reporting workflows for hospital and reference lab customers.
- DNAnexus: DNAnexus provides a cloud-based genomics data analysis and collaboration platform used by clinical labs, research institutions, and pharma. It overlaps with Lucid's cloud-native secondary/tertiary analysis positioning and AWS-hosted SaaS delivery model.
- Velsera (formerly Seven Bridges): Velsera offers a genomics analytics platform for clinical and research use cases including variant interpretation and cohort analysis. It competes for similar multi-omics and clinical genomics SaaS budgets across hospital labs and biopharma.
- Sophia Genetics: Sophia Genetics offers an AI-driven clinical genomics platform for variant interpretation and multimodal data analysis across rare disease and oncology. It directly competes for clinical laboratory and hospital systems that Lucid targets, particularly in European markets.
Emerging players
- Golden Helix: Golden Helix provides clinical genomic analysis and variant annotation software focused on hereditary disease and cancer diagnostics. It serves a similar medical geneticist and clinical laboratory buyer base as Lucid, with partial overlap in tertiary analysis workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Lucid Genomics social profiles
Digital presenceLucid Genomics compliance and trust
Trust signalCompliance1 record
Lucid Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucid Genomics leadership team
Management profileNumber of profiles
Profiles8 records
Lucid Genomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucid Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucid Genomics
What does Lucid Genomics do?
Lucid Genomics provides a cloud-native AI-powered SaaS platform for secondary and tertiary analysis of long-read genomic sequencing data. The platform analyzes 100% of the genome including coding and non-coding (dark genome) regions, performing variant detection, prioritization, interpretation, reporting, and clinical trial matching. It integrates multi-omics data (RNA-seq, methylation, Hi-C, epigenetics) and 3D genome architecture to support individual, family, and cohort-level analysis for clinical diagnostics, research, and drug discovery.
Is Lucid Genomics a public or private company?
Lucid Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lucid Genomics founded?
Lucid Genomics was founded in 2024. It employs 1 to 10 people.
Where is Lucid Genomics based?
Lucid Genomics is headquartered in Berlin, Germany, in the Europe region.
How does Lucid Genomics make money?
One revenue line is on record: B2B SaaS Platform Subscription.
Who are Lucid Genomics's main competitors?
Broad incumbents on record are Illumina DRAGEN, PacBio SMRT Link / HiFi Analysis Tools, Oxford Nanopore EPI2ME and QIAGEN Clinical Insight (QCI). Direct peers are Congenica, Fabric Genomics (formerly Omicia), DNAnexus, Velsera (formerly Seven Bridges) and Sophia Genetics. Golden Helix is listed as an emerging player.
Does Lucid Genomics have an API?
No public API is recorded for Lucid Genomics.
What industry is Lucid Genomics in?
Lucid Genomics's product category is Genomic Data Analysis Software. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 3826.